10x Genomics, Inc…
USUSD10x Genomics, Inc. (US:TXG) — Biotechnology: Laboratory Analytical Instruments. Брой борси, на които се търгуват акциите на компанията: 2. На тази страница — цена и график, дивиденти, най-големи акционери и история на броя на акциите.
За компанията
- Уебсайт
- 10xgenomics.com
- Сектор
- Industrials · Biotechnology: Laboratory Analytical Instruments
- Централа
- Pleasanton, United States
- Изпълнителен директор
- Dr. Serge Saxonov Ph.D.
- Служители
- 1 178
- Основана
- 2012
- Акции в обращение
- 120.21 млн
- Свободно търгуеми акции
- 118.19 млн
- Пазарна капитализация
- 11.53 млрд USD
- Инсайдери
- 1.46%
- Институционални инвеститори
- 120.2%
- Отрасъл (SIC)
- Laboratory Analytical Instruments
- ISIN
- US88025U1097
- LEI
- 5493003Z6741WNLG7H43
- Коефициент на изплащане
- 0%
- FCF
- 121 млн USD
- Дълг
- 0 USDнетни парични средства
- Дивидентна история
- —
- Печалба, FCF и изплатени дивиденти — за 12-те месеца до 30.06.2026 (последният отчет на компанията).
Описание
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Дивиденти
Не са намерени дивидентни плащания (проверено 09.10.2026). Вероятно компанията не изплаща дивиденти.
Новини тази седмица
Все още няма новини от сайта на компанията.
Най-големи притежатели
| Притежател | Дял | Акции | Дата на доклада |
|---|---|---|---|
| FMR, LLC | 14.67% | 17.63 млн | 2026-06-30 |
| Blackrock Inc. | 8.99% | 10.8 млн | 2026-06-30 |
| ARK Investment Managemen… | 8.32% | 10 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 5.81% | 6.98 млн | 2026-06-30 |
| Quantinno Capital Manage… | 4.55% | 5.47 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4.23% | 5.08 млн | 2026-06-30 |
| Price (T.Rowe) Associate… | 3.78% | 4.54 млн | 2026-06-30 |
| Sumitomo Mitsui Trust Gr… | 3.49% | 4.19 млн | 2026-06-30 |
| Amova Asset Management A… | 3.49% | 4.19 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.94% | 3.53 млн | 2026-06-30 |
| Morgan Stanley | 2.79% | 3.35 млн | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.53% | 3.04 млн | 2026-07-31 |
| ARK ETF Trust-ARK Genomi… | 2.53% | 3.04 млн | 2026-08-31 |
| ARK ETF Trust-ARK Innova… | 2.5% | 3.01 млн | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 2.12% | 2.55 млн | 2026-06-30 |
| Fidelity Select PORT.s-S… | 1.66% | 2 млн | 2026-07-31 |
| Fidelity Rutland Square… | 1.37% | 1.65 млн | 2026-07-31 |
| Fidelity Select Portfoli… | 1.34% | 1.61 млн | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.22% | 1.47 млн | 2026-06-30 |
| T. Rowe Price New Horizo… | 1.21% | 1.46 млн | 2026-06-30 |
| SAXONOV SERGE WILSON (Ch… | ≈1.11% | 1.34 млн | 2026-09-22 |
| HINDSON BENJAMIN J (Pres… | ≈0.41% | 488 182 | 2026-08-24 |
| STUELPNAGEL JOHN R (Dire… | ≈0.27% | 328 436 | 2026-09-03 |
| TAICH ADAM (Chief Financ… | ≈0.26% | 316 344 | 2026-09-09 |
| MATEO ALAN V. (Director) | ≈0.07% | 85 877 | 2026-06-04 |
| KOSARAJU SRIDHAR (Direct… | ≈0.06% | 68 278 | 2026-06-04 |
| POPOVITS KIMBERLY J (Dir… | ≈0.03% | 37 445 | 2026-06-04 |
| TEICHMANN SARAH A. (Dire… | ≈0.02% | 28 058 | 2026-08-14 |
| SULIMAN SHEHNAAZ (Direct… | ≈0.02% | 23 792 | 2026-09-22 |
